A reprogramming-based strategy for drug repositioning in patients with mitochondrial DNA-associated Leigh syndrome
Description of the granted funding
Mitochondrial DNA (mtDNA)-associated Leigh syndrome (MILS) is a severe early-onset brain disease affecting 1/100,000 newborns, with no treatments. Drug discovery is challenged by e.g. lack of mtDNA editing methods for transgenic models. Our consortium will employ reprogramming derived MILS neural cells in a large-scale market drug screen, for which we have proof-of-concept: we identified specific enzyme inhibitors as a potential therapy for MILS, with preliminary promising effects in compassionate treatment trials. Here, we extend this approach to a library of repurposable compounds, and validate hits by multi-omics analysis of e.g. neural progenitor and neuronal lines. Our consortium will identify drugs suited for repositioning in MILS, laying the foundation for a multi-national clinical trial and a concrete path towards a cure. We will establish a paradigmatic pipeline for reprogramming-driven drug discovery for rare neurological disorders.
Show moreStarting year
2021
End year
2024
Granted funding
Funder
Research Council of Finland
Funding instrument
Kansainvälinen yhteisrahoitteinen ohjelma
Other information
Funding decision number
344744
Fields of science
Biomedicine
Research fields
Biolääketieteet
Identified topics
brain, neuroscience